![]() |
Back |
Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights |
To participate on the live call, please dial 888-220-8451 (domestic) or +1-323-794-2588 (international), and provide the conference code 2893286 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. About Fibrocell Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Trademarks Fibrocell, the Fibrocell logo, and Investor & Media Relations Contact: |
![]() ![]() ![]() ![]() ![]() |